US10117859B2ActiveUtilityPatentIndex 49
Dosage suspensions of active pharmaceutical ingredients
Est. expiryJun 27, 2036(~10 yrs left)· nominal 20-yr term from priority
A61K 31/444A61K 31/5375A61K 31/439A61K 45/06A61K 9/10A61K 47/44A61K 9/14A61K 31/46
49
PatentIndex Score
0
Cited by
7
References
11
Claims
Abstract
Methods for preparing suspensions of active pharmaceutical ingredients for ensuing drug delivery. The suspension may include a mixture of a relatively low dosage API and a relatively high dosage API or a mixture of an API with a suitable excipient.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A method for forming a drug suspension comprising:
a) providing a first active pharmaceutical ingredient (API-1);
b) providing a second active pharmaceutical ingredient (API-2);
c) co-dissolving said API-1 and API-2 in a common solvent;
d) removing said solvent and recovering a mixture of API-1 and API-2; and
e) forming said drug suspension of said mixture of API-1 and API-2 in a liquid carrier, wherein in said drug suspension, API-1 is present at a concentration of 0.1 mg/mL to 10.0 mg/mL and API-2 is present at a concentration of 20.0 mg/mL to 800 mg/mL.
2. The method of claim 1 wherein after removing said solvent and recovering said mixture of API-1 and API-2, said mixture is milled to provide particle sizes in the range of 100 nm to 10 microns.
3. The method of claim 1 wherein after removing said solvent and recovering said mixture of API-1 and API-2, said mixture is wet milled in a liquid carrier to provide particle sizes in the range of 10 nm to 1000 nm.
4. The method of claim 1 wherein said drug suspension is formed in a vegetable oil or organic alcohol.
5. The method of claim 1 wherein API-1 is present in said suspension at a concentration of 0.1 mg/mL to 5.0 mg/mL.
6. The method of claim 1 wherein API-1 is present in said suspension at a concentration of 0.1 mg/mL to 2.5 mg/mL.
7. The method of claim 1 wherein API-2 is present in said suspension at a concentration of 20.0 mg/mL to 600.0 mg/mL.
8. The method of claim 1 wherein API-2 is present in said suspension at a concentration of 20.0 mg/mL to 400.0 mg/mL.
9. The method of claim 1 wherein API-2 is present in said suspension at a concentration of 20.0 mg/mL to 200.0 mg/mL.
10. The method of claim 1 wherein API-1 comprises a muscarinic antagonist.
11. The method of claim 1 wherein API-2 comprises an oxime.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.